L'Oréal's Strategic Moves in Medical Beauty-Investments and Innovations

In August, L 'Oreal announced the acquisition of a 10 per cent stake in Swiss skincare group Galderma.

Through this acquisition, the two parties will establish a strategic research partnership in dermatology, skin biology, diagnostic tools and evaluation tools.

In addition, in March this year, L 'Oreal's brand Xiu Li Co launched the brand's first class III medical device product - "platinum research" collagen needle,recombinant type III humanized collagen solution for injection.

In fact, as early as 2023, L 'Oreal reached a cooperation with Jinbo Biology, and Jinbo Biology became the OEM of L 'Oreal Sulliko collagen injection products.

According to L 'Oreal's latest financial data, in the first three quarters of 2024, the skin Science and Beauty division is the fastest growing of the five departments, with a year-on-year growth of 11.3% to 5.393 billion euros (about 41.173 billion yuan).

This data once again highlights the importance and growth potential of cosmetic skin science in L 'Oreal's overall business.

A landmark event is that in mid-February 2023, L 'Oreal renamed its active health cosmetics department to L 'Oreal Skin Medical Beauty Department, and officially laid out the skin medical beauty track.